Hypocomplementemia is associated with more severe renal disease and worse renal outcomes in patients with ANCA-associated vasculitis: a retrospective cohort study

Aglaia Chalkia\textsuperscript{a}, Konstantinos Thomas\textsuperscript{b}, Panagiota Giannou\textsuperscript{a}, Alexandros Panagiotopoulos\textsuperscript{b}, Emilia Hadziyannis\textsuperscript{b}, Athanasia Kapota\textsuperscript{a}, Harikleia Gakiopoulou\textsuperscript{c}, Dimitrios Vassilopoulos\textsuperscript{b} and Dimitrios Petras\textsuperscript{a}

\textsuperscript{a}Nephrology Department, Hippokration General Hospital, Athens, Greece; \textsuperscript{b}2nd Department of Medicine and Laboratory, Clinical Immunology – Rheumatology Unit, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; \textsuperscript{c}1st Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

**ABSTRACT**

**Background:** The complement system has been recently proposed to play an important role in the pathogenesis of ANCA-associated vasculitis (AAV). This study evaluated the value of serum and kidney deposited C3 in predicting renal outcomes in AAV.

**Methods:** This was a retrospective study of 47 patients with AAV, who were categorized according to their serum C3 levels as hypo- or normocomplementemic and to those with positive or negative kidney biopsy immunofluorescence (IF) for C3. Baseline characteristics as well as progression to end-stage renal disease (ESRD) between the 2 groups were compared.

**Results:** In total, 23% (11/47) were hypo-complementemic; these patients were older (74 vs. 65 years, \(p = 0.013\)), had higher creatinine levels (4.9 vs. 2.2 mg/dL, \(p = 0.006\)), were more often hemodialysis dependent (64% vs. 19%, \(p = 0.009\)) and progressed more often to ESRD (55% vs. 11%, \(p = 0.01\)) compared to normo-complementemic patients (\(n = 36\)). On multivariate analysis, serum creatinine at diagnosis (HR = 16.8, 95%CI: 1.354–208.62, \(p = 0.028\)) and low serum C3 (HR = 2.492; 95% CI: 1.537–11.567; \(p = 0.044\)) were independent predictors for ESRD. Among 25 patients with an available kidney biopsy, 56% had C3 deposition by IF and displayed more often a mixed histological pattern (72% vs. 27%, \(p = 0.033\)), low serum C3 levels (42% vs. 18%, \(p < 0.001\)) and serious infections during follow-up (57% vs. 18%, \(p = 0.047\)) compared to those with negative (\(n = 11\)) IF staining.

**Conclusion:** Almost one of four patients with AAV has low C3 levels at diagnosis which is associated with more severe renal disease and worse renal outcomes (ESRD). This should be taken into account in therapeutic and monitoring strategies.

**ARTICLE HISTORY**

Received 25 May 2020
Revised 20 July 2020
Accepted 20 July 2020

**KEYWORDS**

ANCA; complement; glomerulonephritis; vasculitis; end-stage renal disease

**Introduction**

Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a systemic small vessel vasculitis with multiorgan involvement and significant associated morbidity and mortality. The role of complement activation, mainly of the alternative pathway, in its pathogenesis has been recently suggested to be significant [1]. Although necrotizing and crescentic glomerulonephritis related to ANCAAs is typically referred as a “pauci-immune” process, in certain cases there is immune complex and complement deposition in glomeruli as detected by immunofluorescence (IF) [2]. Kidney complements deposits of patients with AAV correlated with greater kidney damage, more significant proteinuria, and overall disease activity [3]. Nevertheless, data regarding the prognostic significance of low C3 levels and C3 kidney deposition in patients with AAV are limited.

Hence, the aim of this study was to investigate the potential correlation of C3 in the serum and kidneys with renal characteristics and prognosis in a cohort of patients with AAV.

**Patients and methods**

This was a retrospective cohort study of patients with AAV followed in a tertiary referral hospital (Nephrology Department, Hippokration General Hospital, Athens, Greece). The study was approved by the institutional review board of the hospital. All patients provided written informed consent for inclusion before enrolment. The study was conducted in accordance with the Declaration of Helsinki.

**CONTACT** Aglaia Chalkia aglaia.chalkia@gmail.com Nephrology Department, Hippokration General Hospital, Vasilissis Sofias 108, Athens 11527, Greece

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
### Table 1. Baseline patient characteristics, therapy, and disease outcomes according to their serum C3 levels.

|                          | Total n = 47 | Hypocomplementemic (C3 < 75 mg/dL) n = 11 | Normocomplementemic (C3 > 75 mg/dL) n = 36 | p-value |
|--------------------------|--------------|------------------------------------------|------------------------------------------|---------|
| **Age, years, median (IQR)** | 67 (55.7–75.9) | 74 (66.3–80.4) | 64.6 (53.5–73.2) | 0.013   |
| **Males, n (%)**         | 25 (53%)     | 6 (55%)                                  | 19 (54%)                                 | 0.918   |
| **AAV type**             |              |                                          |                                          | 0.291   |
| GPA, n (%)               | 26 (55%)     | 5 (45%)                                  | 22 (61%)                                 |         |
| MPA, n (%)               | 17 (36%)     | 6 (55%)                                  | 10 (28%)                                 |         |
| RLV, n (%)               | 4 (9%)       | 0 (0%)                                   | 4 (11%)                                  |         |
| **ANCA status**          |              |                                          |                                          | 0.089   |
| Anti-MPO+, n (%)         | 27 (57.4%)   | 5 (45%)                                  | 22 (61%)                                 |         |
| Anti-PR3+, n (%)         | 15 (32%)     | 3 (27%)                                  | 12 (33%)                                 |         |
| Positive, n (%)          | 2 (4.2%)     | 1 (9%)                                   | 2 (6%)                                   |         |
| **Low serum C4 mg/dL, n (%)** | 1 (2%) | 1 (9%) | 0 (0%) | 0.234 |
| **ANA, anti-DNA positive, n (%)** | 0 (0%) | 0 (0%) | 0 (0%) | 1 |
| **Organ involvement**    |              |                                          |                                          |         |
| Cutaneous signs, n (%)   | 7 (15%)      | 1 (9%)                                   | 6 (17%)                                  | 1       |
| Ear, nose, throat, n (%) | 14 (30%)     | 3 (27%)                                  | 11 (31%)                                 | 0.835   |
| Peripheral Nervous System, n (%) | 12 (26%) | 1 (9%) | 11 (31%) | 0.413 |
| Joints, n (%)            | 19 (40%)     | 3 (27%)                                  | 16 (44%)                                 | 0.732   |
| Lung involvement, n (%)  | 32 (68%)     | 10 (91%)                                 | 22 (61%)                                 | 0.078   |
| Pulmonary Hemorrhage, n (%) | 6 (13%) | 3 (27%) | 3 (8%) | 0.131 |
| Kidney involvement, n (%) | 40 (85%)    | 11 (100%)                                | 29 (81%)                                 | 0.175   |
| Hematuria, n (%)         | 24 (51%)     | 7 (64%)                                  | 17 (47%)                                 | 0.636   |
| Proteinuria, >1g/24h     | 18/32 (56%)  | 8/10 (80%)                               | 10/22 (45%)                              | 0.26    |
| (data from 32 patients)  |              |                                          |                                          |         |
| **Serum creatinine (mg/dL), median (IQR)** | 2 (1–4.4) | 5.2 (3–6.5) | 1.25 (0.9–3) | 0.006 |
| **Hemodialysis, n (%)**  | 14 (30%)     | 7 (64%)                                  | 7 (19%)                                  | 0.009   |
| (among 40 patients with renal involvement) | | | | |
| Histological type        |              |                                          |                                          | 0.173   |
| Mixed, n (%)             | 13 (52%)     | 4 (50%)                                  | 9 (53%)                                  |         |
| Focal, n (%)             | 7 (28%)      | 1 (13%)                                  | 6 (35%)                                  |         |
| Sclerotic, n (%)         | 3 (12%)      | 1 (13%)                                  | 2 (12%)                                  |         |
| Crescentic, n (%)        | 2 (8%)       | 2 (25%)                                  | 0 (0%)                                   |         |
| Positive IF for C3, n (%) | 14/25 (56%) | 6/8 (75%) | 8/17 (47%) | 0.234 |
| **Induction Therapy (n = 47)** | | | | |
| CYC, n (%)               | 22 (47%)     | 7 (64%)                                  | 15 (42%)                                 | 0.624   |
| RTX, n (%)               | 15 (32%)     | 2 (18%)                                  | 13 (36%)                                 |         |
| CYC + RTX, n (%)         | 6 (13%)      | 2 (18%)                                  | 4 (11%)                                  |         |
| MTX/MMF, n (%)           | 4 (8%)       | 0 (0%)                                   | 4 (11%)                                  |         |
| Plasmapheresis, n (%)    | 9 (19%)      | 4 (36%)                                  | 5 (14%)                                  | 0.183   |
| **Maintenance**          |              |                                          |                                          | 0.218   |
| Therapy (n = 36)*        |              |                                          |                                          |         |
| RTX, n (%)               | 29 (62%)     | 8 (73%)                                  | 21 (58%)                                 |         |
| AZA, n (%)               | 4 (9%)       | 1 (9%)                                   | 3 (8%)                                   |         |
| MMF, n (%)               | 3 (6%)       | 1 (9%)                                   | 2 (5%)                                   |         |
| Relapses, n (%)          | 18 (38%)     | 3 (27%)                                  | 15 (42%)                                 | 0.299   |
| ESRD, n (%)              | 10 (21%)     | 6 (55%)                                  | 4 (11%)                                  | 0.01    |
| Mortality, n (%)         | 8 (17%)      | 2 (18%)                                  | 6 (17%)                                  | 0.1     |
| ESRD and/or mortality, n (%) | 12 (26%) | 6 (55%) | 6 (17%) | 0.02   |

Values are expressed as numbers of patients (n), or median interquartile ranges (IQR). AAV, ANCA associated vasculitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; RLV, renal-limited vasculitis; ANCA, antineutrophil cytoplasmic antibodies; MPO, myeloperoxidase; PR3, proteinase 3; Double positive, anti-GBM (+) and ANCA (+); C4, complement 4; IF, immunofluorescence; CYC, cyclophosphamide; RTX, rituximab; MTX, methotrexate; MMF, mycophenolate mofetil; AZA, azathioprine; ESRD, end-stage renal disease. Statistical significant differences are shown in bold (p < 0.05).

*Four patients who died in the induction phase and seven patients without detailed data available were excluded.

Department and Clinical Immunology—Rheumatology Unit, 2nd Department of Medicine, Hippokration General Hospital, Athens, Greece) through the years 2002 and 2019. Among 62 patients of the Caucasian race with newly diagnosed AAV, 47 patients with available complement levels at diagnosis were included in the study. All patients with AAV satisfied the inclusion criteria of ACR 1990 or the Chapel Hill Consensus Conference definitions [4] for granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and
ANCA-limited renal vasculitis (LRV). Patients with other underlying diseases that cause secondary vasculitis, such as systemic lupus erythematosus, rheumatoid arthritis, IgA nephropathy, Sjogren’s syndrome, malignancy and Behcet’s disease were excluded clinically and serologically. There was no temporal relationship between clinically evident vasculitis and the administration of an offending drug. So, drug-induced vasculitis was also excluded. The patients, who included in the study, met one of the two following criteria: 1. Necrotizing vasculitis predominantly affecting small vessels and/or necrotizing glomerulonephritis with few or no immune deposits 2. positive ANCA with IF and ELISA. The study was approved by the Hippokration General Hospital’s institutional review board (57/26-3-2018) and the consent of all patients for their retrospective chart review was obtained.

Demographic data were collected for each patient (age, sex, type of AAV, and patient follow-up). Clinical characteristics at diagnosis, such as major organ involvement (lung: pulmonary hemorrhage, kidney: hemodialysis dependence) and induction treatment (with or without plasmapheresis), episodes of relapses, and serious infections during follow-up and eventually mortality.

As far as laboratory results, hemoglobin, creatinine level, 24-h proteinuria, hematuria, ANCA status (p-ANCA MPO, c-ANCA PR3, double positivity [anti-GBM with ANCA] or negative), serum C3, C4 and ANA, and anti-dsDNA were included. C3 and C4 levels were assessed by tholosimetry. Anti-neutrophil cytoplasmic antibodies (c-ANCA and p-ANCA) were determined by a direct IF technique and the specificity for PR3 and MPO by ELISA. The serum C3 reference range in our laboratory was 75–180 mg/dL. The patients were divided into 2 groups, those with low C3 (hypo-complementemic: <75 mg/dL), and those with normal C3 (normo-complementemic: 75–180 mg/dL). No one had C3 levels higher than 180 mg/dL.

A total of 40 patients presented with renal involvement, which was defined by the presence of 24-h urine proteinuria of >1 g, active urinary sediment (leukocyturia > 5 white blood cells/field, hematuria >5 erythrocytes/field, and/or cellular casts) and/or increase of creatinine values over 1.2 mg/dL. Kidney biopsy was performed in 25 patients (62.5%). Renal histology was evaluated using light microscopy (hematoxylin and eosin, periodic acid-Schiff, and Masson trichrome stains) and was classified into 4 histological subtypes according to the 2010 histologic classification of AAV [5]. Those presenting ≥50% of all glomeruli globally sclerosed were sclerotic type and those with ≥50% normal glomeruli were classified as focal type. Those showing ≥50% of glomeruli with semilunar cells were classified as crescentic type and those not presenting the anterior criteria were classified as mixed type. The presence of immunoglobulin (IgG, IgM, IgA), complement (C3, C1q, C4), kappa and lambda light chains was evaluated by direct IF on the fresh frozen tissue. The staining of C3 was routinely performed using polyclonal rabbit antihuman antiserum, at dilution 1:50 (Dako, Copenhagen, Denmark). According to their C3 deposition for at least 1+ in a 0–4+ scale, patients were divided into those with (+) and (−) IF. Electron microscopy was not performed.

**Statistical analysis**

Data were analyzed using Statistical Package for the Social Sciences (SPSS) software program, version 19.0 for Windows (SPSS, Chicago, IL, USA). Values are expressed as medians and interquartile ranges (IQR) for continuous variables and percentages for categorical variables. Comparison of variables was done using the independent samples t-Test for Continuous variables and Chi-square test or Fisher’s exact test for categorical variables. A two-sided value *p* < 0.05 was considered as statistically significant. To address the independent predictive value of factors associated with the progression to end-stage renal disease (ESRD—defined as eGFR < 15 mL/min/1.73 m² or requiring hemodialysis) a univariate and multivariate Cox proportional hazards regression analysis were performed. We used the variables with *p* values of less than 0.1 between progressors to ESRD and non-progressors.

**Results**

**Baseline patient characteristics**

Forty-seven patients with AAV were included; 53% (25/47) were men, with a median age of 67 years (Table 1). The most frequent type of vasculitis was GPA (55%), followed by MPA (36%) and LRV (9%). The majority of patients were ANCA+ (94%), most of them with MPO specificity (57%).

Forty patients (85%) had renal involvement at diagnosis and approximately one third (30%, 14/47) required hemodialysis. The median serum creatinine at diagnosis was 2 mg/dL while 56% (18/32) of patients had significant proteinuria (>1 g/24h) (32 patients with available data concerning proteinuria). In 25 patients a kidney biopsy was performed. Approximately half (52%) of patients had a mixed histologic pattern, followed by focal (28%), sclerotic (12%) and crescentic (8%) types.
In 68% of the patients, who included, presented with lung involvement and among them 6 (13%) presented with pulmonary hemorrhage (Table 1).

**Treatment and disease outcomes**

The induction therapeutic regimen consisted of glucocorticoids (three daily pulses of methylprednisolone 1000 mg followed by prednisolone 1 mg/kg per day with gradual dose taper) and immunosuppressives (cyclophosphamide—CYC: 47%, rituximab—RTX: 32%, CYC + RTX: 13%, mycophenolate mofetil—MMF or methotrexate—MTX: 8%, Table 1). In 19% plasmapheresis was added to the induction regimen.

Patients were followed for a median time of 56 months (range: 4-204 months). Among patients who received maintenance therapy (n = 36, Table 1), the majority received RTX (62%) followed by AZA (9%) or MMF (6%). During the follow-up period, 38% of patients (18/47) developed relapses (minor and major). Among them, nine patients received RTX, two patients CYC, and two patients CYC + RTX as rescue therapy.

Finally, 10 patients (21%) progressed to ESRD and 8 (17%) died (4 during the induction and 4 during the follow-up period). The causes of death were serious infections in 3 patients, lung cancer in 1 patient, heart disease in 1 and unknown causes in 4 patients. It is noteworthy that the two patients with double positivity (ANCA and anti-GBM) at diagnosis progressed to ESRD between 3-6 months of disease duration.

**Differences between hypo- and normocomplementemic patients**

At baseline, 23% (11/47) of the patients had low C3 levels (<75 mg/dL, Table S1 in Supplementary Material). Compared to normo-complementemic patients, those with low C3 were older (median age 74 vs. 64.6 years, p = 0.013), had higher serum creatinine at diagnosis (5.2 vs. 1.25 mg/dL, p = 0.006), required more often hemodialysis at diagnosis (64 vs. 19%, p = 0.009), and progressed more frequently to ESRD (55 vs. 11%, p = 0.01) (Table 1).

**Differences between C3 kidney positive and negative patients**

Kidney biopsies were available in 25/40 (62.5%) patients with renal involvement. Compared to patients without kidney biopsy (n = 15), those with renal biopsy available had more frequently significant proteinuria and higher serum creatinine at diagnosis (Table 2).

Among those 25 kidney biopsies, more than half (56%, 14/25) had C3 deposits by IF. C3 staining, mainly in mesangium, was relatively mild (<20) in all patients. Furthermore, 43% (6/14) of C3 (+) biopsies also showed...
mild IgM staining (1+). The IF of the other immunoglobulins and complement components were negative. Additionally, thrombotic microangiopathy was not detected as a pattern of injury in kidney biopsies. Patients with C3 deposition (n = 14) as a group, had more often low C3 levels (43 vs. 18%, p = 0.001), a mixed histologic pattern in kidney biopsy (71 vs. 27%, p = 0.001), and a higher rate of serious infections during follow-up (50% vs. 32%, p = 0.001) compared to those without C3 deposition (n = 11) (Table 3).

Factors associated with progression to ESRD

Ten patients (21%) progressed to ESRD during follow-up. Compared to patients who did not progress to ESRD (n = 37), these patients (n = 10) were older (73 vs. 58 years, p = 0.04), had higher creatinine level (5.9 vs 1.6 mg/dL, p = 0.000), proteinuria > 1 g/24 h (70% vs. 30%, p = 0.120) and lower serum C3 levels (60% vs 14%, p = 0.006), had more often double positivity [anti-GBM with ANCA] (20% vs. 0%, p = 0.014) at diagnosis and sclerotic histological pattern (30% vs 0%, p = 0.03), more frequently required hemodialysis at diagnosis (70% vs 8%, p = 0.000) and developed serious infection at follow-up (50% vs 32%, p = 0.045).

Univariate Cox regression analysis revealed different risk factors associated with progression to ESRD such as high serum creatinine at diagnosis, increasing age, need for hemodialysis at diagnosis, positive ANCA, presence of significant proteinuria (>1 g/24h), low serum C3 and high rate of serious infections during follow-up. By multivariate analysis, only serum creatinine at diagnosis (HR = 16.8, 95% CI = 1.354 – 208.62, p = 0.028) and low serum C3 (HR = 2.492, 95% CI = 1.537–11.537, p = 0.044) remained statistically significant (Table 4).

Discussion

This study highlights a potential association between low serum C3 levels at diagnosis and renal severity as well as renal prognosis in patients with AAV. This is one of the few studies showing that serum hypocomplementemia at diagnosis may be an independent prognostic factor for ESRD progression in patients with AAV.

A role for complement activation in the pathogenesis of ANCA disease is supported by in vitro studies [6,7], histologic data from kidney biopsies showing complement deposition [8] as well as data from animal models and humans [9,10] indicating that inhibition of complement may be therapeutically efficacious in AAVs. These studies demonstrated that the complement activation by alternative pathway and particularly the receptor C5a (C5aR) is important in the maintenance of the inflammatory process. Two inhibitors of the complement pathway are in clinical development for ANCA vasculitis: avacopan, an oral C5a receptor inhibitor, that has demonstrated efficacy, safety and steroid sparing in two Phase II trials, being it a promising future strategy and eculizumab, a monoclonal antibody that targeted against complement C5, which inhibits the cleavage of C5 into C5a and C5b [9,10]. Furthermore, the positive effect of plasma exchange in severe AAV is hypothetically due, at least in part, to the removal of activated complement factors and of chemotaxins [10]. However, whether or not serum or kidney deposited C3

Table 3. Clinical and histological characteristics of patients according to their kidney C3 deposition by IF.

|                      | C3 IF (+/+ ++) (n = 14) | C3IF negative (n = 11) | p-value   |
|----------------------|------------------------|------------------------|-----------|
| Age, years, median (IQR) | 71.1 (64.5–79)         | 70.8 (61–73.6)         | 0.975     |
| Creatinine mg/dL, median (IQR) | 3.35 (2.1–5.8)         | 4 (1.2–5.2)            | 0.557     |
| Low serum C3, n (%) | 6 (43%)                | 2 (18%)                | 0.001     |
| Histological type   |                        |                        | 0.033     |
| Mixed, n (%)        | 10 (72%)               | 3 (27%)                |           |
| Crescentic, n (%)   | 1 (7%)                 | 1 (9%)                 |           |
| Focal, n (%)        | 1 (7%)                 | 6 (55%)                |           |
| Sclerotic, n (%)    | 2 (14%)                | 1 (9%)                 |           |
| IgM IF (+)          | 6 (43%)                | 3 (27%)                | 0.065     |
| Hemodialysis, n (%) | 5 (36%)                | 5 (45%)                | 0.697     |
| Plasmapheresis, n (%) | 5 (36%)              | 2 (18%)                | 0.407     |
| Lung involvement, n (%) | 12 (86%)           | 9 (82%)                | 1         |
| Pulmonary hemorrhage, n (%) | 3 (21%)           | 2 (18%)                |           |
| Serious infections, n (%) | 8 (57%)            | 2 (18%)                | 0.047     |
| Relapses, n (%)     | 5 (36%)                | 4 (36%)                | 0.94      |
| ESRD, n (%)         | 5 (36%)                | 3 (27%)                | 0.69      |
| Mortality, n (%)    | 3 (21%)                | 2 (18%)                | 1         |
| ESRD and /or mortality, n (%) | 6 (43%)          | 4 (36%)                | 0.89      |

Values are expressed as numbers of patients, or median interquartile ranges (IQR). C3, complement 3 level; IgM IF, immunoglobulin M immunofluorescence; ESRD, end-stage renal disease; IF, immunofluorescence. Statistical significant differences are shown in bold (p < 0.05).
can be used as markers of disease severity or prognosis (ESRD/death) in patients with AAV is unclear.

Low serum C3 levels have been reported in 4-35% of patients with AAV [3,11–17] (Table 5). In our cohort 23% of patients were hypocomplementemic at diagnosis. There are conflicting literature data regarding the potential association between C3 levels and severity of renal disease. Some studies did not find a significant correlation between hypocomplementemia and creatinine levels [3,13,15–17] whereas others did [11,12,14]. Recently, Garcia et al. [14] in a cohort of 93 patients described low C3 levels in 11% and that was associated significantly not only with higher creatinine levels, but as well with proteinuria > 1g/day and active urinary sediment. Similarly, Villacorta et al. [16] on 111 patients with AAV also described a significant correlation between hypocomplementemia and the need for dialysis at diagnosis.

In our patient cohort, low C3 levels were associated with more severe renal disease (as evidenced by high serum creatinine and need for hemodialysis) and worse renal prognosis (progression to ESRD). Therefore, these findings support the hypothesis of systemic activation of the complement in a proportion of patients with AAV and this could have clinical and prognostic implications.

Table 4. Uni- and multivariate Cox regression analysis of variables associated with ESKD progression.

| References          | Patients | Proportion of low C3 | Impact of low serum C3 |
|---------------------|----------|----------------------|------------------------|
| Age                 |          |                      |                        |
| Serum creatinine at diagnosis |          |                      |                        |
| Hemodialysis at diagnosis |          |                      |                        |
| ANCA (+) status     |          |                      |                        |
| Sclerotic pattern (kidney biopsy) |          |                      |                        |
| Proteinuria >1 g/24h|          |                      |                        |
| Low serum C3 (< 75 mg/dL) |          |                      |                        |
| Positive IF for C3 (kidney biopsy) |          |                      |                        |
| Serious infections during follow-up |          |                      |                        |

Table 5. Association between low C3 levels and C3 IF in AAV and renal disease and outcome.

| References          | Patients | Proportion of low C3 | Impact of low serum C3 |
|---------------------|----------|----------------------|------------------------|
| Garcia et al. [14]  | 93       | 11.1% (7/63)         | Higher frequency of renal involvement (p = 0.036) |
| Fukui et al. [3]    | 81       | 20% (16/81)         | More often skin lesions (p = 0.002), TMA (p = 0.07), Diffuse alveolar hemorrhage (p = 0.006), mortality (p = 0.033) |
| Villacorta et al. [16] | 111     | 35% (39/111)        | Higher creatinine level at diagnosis (p > 0.05) Need for dialysis at onset (p = 0.04) Lower response to treatment (p = 0.007) Poorer renal and overall survival (p = 0.001) Treated more often with PEX (p = 0.04) Poorer renal (p < 0.001) and overall survival (p = 0.0011) |
| Deshayes et al. [15] | 76       | 5% (4/76)           | Lower overall and renal survival (p = 0.016) Older age (p = 0.04) Lower eGFR at diagnosis (p > 0.05) More often ESRD (p = 0.02) Higher creatinine at diagnosis (p = 0.008) Lower C4 level (p = 0.008) Poorer renal (p = 0.001) and overall survival (p = 0.047) |
| Crnogorac et al. [17] | 75       | 12% (9/75)          | Lower eGFR at diagnosis (p > 0.05) More often ESRD (p = 0.02) Higher creatinine at diagnosis (p = 0.008) Lower C4 level (p = 0.008) Poorer renal (p = 0.001) and overall survival (p = 0.047) |
| Manenti et al. [13] | 46       | 35% (16/46)         | Lower overall and renal survival (p = 0.016) Older age (p = 0.04) Lower eGFR at diagnosis (p > 0.05) More often ESRD (p = 0.02) Higher creatinine at diagnosis (p = 0.008) Lower C4 level (p = 0.008) Poorer renal (p = 0.001) and overall survival (p = 0.047) |
| Augusto et al. [11] | 45       | 49% (22/45)         | Lower overall and renal survival (p = 0.016) Older age (p = 0.04) Lower eGFR at diagnosis (p > 0.05) More often ESRD (p = 0.02) Higher creatinine at diagnosis (p = 0.008) Lower C4 level (p = 0.008) Poorer renal (p = 0.001) and overall survival (p = 0.047) |
| Molad et al. [12]   | 30       | 20% (6/30)          | Lower overall and renal survival (p = 0.016) Older age (p = 0.04) Lower eGFR at diagnosis (p > 0.05) More often ESRD (p = 0.02) Higher creatinine at diagnosis (p = 0.008) Lower C4 level (p = 0.008) Poorer renal (p = 0.001) and overall survival (p = 0.047) |
| Haas et al. [25]    | 126      | No data             | Higher proteinuria (p < 0.001) and overall survival (p = 0.02) |
| Chen et al. [24]    | 112      | 0.8% (4/112)        | Higher percentage of glomeruli with crescents (p = 0.06) |
| Scaglioni et al. [23]| 53       | No data             | Higher proteinuria (p = 0.0036) |

C3, complement 3; IF, immunofluorescence; TMA, thrombotic microangiopathy; PEX, plasma-exchange; ESRD, end-stage renal disease; C4, complement 4, p < 0.05 statistical significant.
There has been some evidence from previous studies that serum creatinine at diagnosis could be related to worse prognosis in patients with AAV [18–22]. In our cohort, we found a strong association between serum creatinine at diagnosis and progression to ESRD. The novel finding of our study was that low serum C3 levels were an independent predictor of ESRD progression. Few studies have shown that hypocomplementemia at the presentation of the AAV was associated with worse renal prognosis [11–13,15,17]. Crnogorac et al. [17] included 75 patients with AAV and renal involvement and suggested that low serum C3 at diagnosis could be associated with worse renal prognosis (ESRD). On contrary, Augusto et al. [11] on 45 patients found a significant correlation between even lower normal C3 values at diagnosis with ESRD related mainly to histologic data (crescentic/mixed histologic form).

In the literature, deposits of complement in kidney biopsies have been reported in 25–54% of patients with AAV [16,23,24,25] (Table 5). Hass et al. [25] studied 126 biopsies and found in 54% of them immune complex deposits on electron microscopy. In these studies, C3 deposition was associated with proteinuria [23–25], higher creatinine [24], lower C3 [13] and certain parameters of renal histopathology, such as higher percentage of crescent formation [24,25].

In our study, more than half of patients showed C3 renal deposition. These patients had more often low serum C3 levels, a mixed histologic pattern in kidney biopsies and presented more frequently serious infections during follow-up. However, there was no correlation between kidney C3 deposition and AAV disease severity and prognosis (ESRD).

Our study has certain limitations including its retrospective design, the small number of included patients and the missing data regarding kidney biopsies. On contrary, this is one of the few studies in the literature where complement serum levels and kidney deposition were examined as markers of disease severity and progression during long-term follow-up (~4.5 years).

Our findings are novel indicating that the subgroup of patients with AAV with low C3 at diagnosis has a more severe disease and a higher risk for progression to ESRD. Consequently, more multicentric research studies are needed to confirm our study findings, so this should be taken into account when the appropriate therapeutic and monitoring strategies are designed.

Ethical policy and institutional review board statement

This research was approved by the Hippokration General Hospital’s institutional review board and consent of all patients for their retrospective chart review was obtained.

Acknowledgments

The authors are grateful to all of the participants, other physicians, medical staff, and other contributors to this study.

Disclosure statement

No potential conflict of interest was reported by the author(s).

References

[1] Chen M, Jayne DRW, Zhao M-H. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol. 2017;13(6): 359–367.
[2] Chen Y-X, Xu J, Pan X-X, et al. Histopathological classification and renal outcome in patients with antineutrophil cytoplasmic antibodies-associated renal vasculitis: a study of 186 patients and metaanalysis. J Rheumatol. 2017;44(3): 304–313.
[3] Fukui S, Iwamoto N, Umeda M, et al. Antineutrophil cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis. Medicine. 2016;95:e4871.
[4] Jennette JC, Falk RJ, Bacon PA, et al. Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013 Jan. 2012;65(1):1–11.
[5] Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628–1636.
[6] Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170(1):52–64.
[7] Schreiber A, Xiao H, Jennette JC, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. JASN. 2009;20(2):289–298.
[8] Xing GQ, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol. 2009;29(3):282–291.
[9] Tesar V, Hruskova Z. Avacopan in the treatment of ANCA-associated vasculitis. Expert Opin Investig Drugs. 2018;27(5):491–496.
[10] Manenti L, Urban ML, Maritati F, et al. Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives. Intern Emerg Med. 2017;12(6):727–731.
[11] Augusto JF, Langs V, Demiselle J, et al. Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis. PLoS One. 2016;11(7):e0158871.
[12] Molad Y, Tovar A, Ofer-Shiber S. Association of low serum complement C3 with reduced patient and renal
survival in anti myeloperoxidase-associated small-vessel vasculitis. Nephron Clin Pract. 2014;126(1):67–74.

[13] Manenti L, Vaglio A, Gnappi E, et al. Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis. Clin J Am Soc Nephrol. 2015;10(12):2143–2151.

[14] Garcia L, Pena CE, Aguila MR, et al. Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study. Clin Rheumatol. 2019;38(10):2819–2824.

[15] Deshayes S, Aouba A, Khoy K, et al. Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. PLoS One. 2018;13(4):e0195680.

[16] Villacorta J, Diaz-Crespo F, Acevedo M, et al. Circulating C3 levels predict renal and global outcome in patients with renal vasculitis. Clin Rheumatol. 2016;35(11):2733–2740.

[17] Crnogorac M, Horvatic I, Kacinari P, et al. Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome. J Nephrol. 2018;31(2):257–262.

[18] Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452–3462.

[19] Rhee RL, Hogan SL, Poulton CJ, et al. Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis & Rheumatology. 2016;68(7):1711–1720.

[20] Flossmann O, Berden A, de Groot K, Westman K et al.; European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488–494.

[21] Walsh M, Flossmann O, Berden A, et al.; European Vasculitis Study Group. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64(2):542–548E.

[22] Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58(9):2908–2918.

[23] Scaglioni V, Scolnik M, Catoggio LJ, et al. ANCA-associated pauci-immune glomerulonephritis: always pauci-immune?. Clin Exp Rheumatol. 2017;35(103):55–58.

[24] Chen M, Xing GQ, Yu F, et al. Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant. 2008;24(4):1247–1252.

[25] Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int. 2004;65(6):2145–2152.